Payment overview · 2025
General Payments
$101.76
5 reported records · 4 companies
Healthcare provider profile · identity verified
Mitchell Andrew Pullias, MD
Allopathic & Osteopathic Physicians|Pediatrics · SMYRNA, TN · NPI 1215926860
Verified facts
What the public records show
CMS Open Payments records show Mitchell Andrew Pullias, MD received $101.76 in general payments during 2025 across 5 reported records.
Astellas Pharma US Inc accounted for 47.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $47.90 | 47.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $22.38 | 22.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.76 | 15.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.72 | 15.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $101.76 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $47.90 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $22.38 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.76 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.76 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $15.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
53 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 300 | 88 |
| Amlodipine Besylate | Amlodipine Besylate | 245 | 69 |
| Levothyroxine Sodium | Levothyroxine Sodium | 221 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 188 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 116 | 32 |
| Metformin Hcl | Metformin Hcl | 104 | 28 |
| Omeprazole | Omeprazole | 102 | 30 |
| Lisinopril | Lisinopril | 101 | 30 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 99 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 84 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 83 | 24 |
| Losartan Potassium | Losartan Potassium | 82 | 17 |
| Carvedilol | Carvedilol | 78 | 20 |
| Simvastatin | Simvastatin | 70 | 19 |
| Trazodone Hcl | Trazodone Hcl | 69 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 66 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 64 | 40 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 62 | 17 |
| Clonazepam | Clonazepam | 59 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 57 | 11 |
| Furosemide | Furosemide | 55 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 54 | 17 |
| Eliquis | Apixaban | 53 | 13 |
| Meloxicam | Meloxicam | 52 | 19 |
| Metformin Hcl Er | Metformin Hcl | 51 | 16 |
| Allopurinol | Allopurinol | 49 | 15 |
| Prednisone | Prednisone | 49 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 13 |
| Potassium Chloride | Potassium Chloride | 43 | 14 |
| Celecoxib | Celecoxib | 42 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 41 | suppressed |
| Telmisartan | Telmisartan | 41 | 12 |
| Glipizide | Glipizide | 39 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 38 | 12 |
| Clonidine Hcl | Clonidine Hcl | 37 | suppressed |
| Gabapentin | Gabapentin | 36 | 13 |
| Glimepiride | Glimepiride | 35 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 35 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 34 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 34 | 11 |
| Famotidine | Famotidine | 32 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 32 | suppressed |
| Ozempic | Semaglutide | 31 | suppressed |
| Pregabalin | Pregabalin | 31 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 31 | 12 |
| Finasteride | Finasteride | 30 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 30 | suppressed |
| Jardiance | Empagliflozin | 29 | suppressed |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 27 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 16 |
| Irbesartan | Irbesartan | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 14 |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $101.76 · 5 records | Astellas Pharma US Inc | NURTEC ODT, VOQUEZNA, VRAYLAR, Veozah, ZAVZPRET | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error